Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raily Aesthetic Medicine International Holdings (HKSE:02135) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Raily Aesthetic Medicine International Holdings EBITDA Margin % Related Terms
Raily Aesthetic Medicine International Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raily Aesthetic Medicine International Holdings EBITDA Margin % Chart
Raily Aesthetic Medicine International Holdings Annual Data
HKSE:02135 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Raily Aesthetic Medicine International Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raily Aesthetic Medicine International Holdings EBITDA Margin % vs Healthcare Providers & Services Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raily Aesthetic Medicine International Holdings (HKSE:02135) has a EBITDA Margin % of 19.40% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Raily Aesthetic Medicine International Holdings and its competitors. This is 45% above median its historical median of 13.34. According to the industry distribution chart, Raily Aesthetic Medicine International Holdings ranks #278 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 41.9%.
Is Raily Aesthetic Medicine International Holdings' EBITDA Margin % too high?
Raily Aesthetic Medicine International Holdings' current EBITDA Margin % of 19.40% is 45% above median its 10-year median of 13.34. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Raily Aesthetic Medicine International Holdings' value of 19.40% is 89.5% above this industry median. Based on the distribution chart, Raily Aesthetic Medicine International Holdings ranks #278 out of 664 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raily Aesthetic Medicine International Holdings has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raily Aesthetic Medicine International Holdings' EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Raily Aesthetic Medicine International Holdings ranks #278 out of 664 companies for EBITDA Margin %. This puts Raily Aesthetic Medicine International Holdings in the upper half of its industry. The industry median EBITDA Margin % is 10.24. Raily Aesthetic Medicine International Holdings' value of 19.40% is 89.5% above this benchmark. While the company's 10-year median is 13.34 vs. the industry median of 10.24, Raily Aesthetic Medicine International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raily Aesthetic Medicine International Holdings's current EBITDA Margin % of 19.40% is 89.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Raily Aesthetic Medicine International Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raily Aesthetic Medicine International Holdings's current EBITDA Margin % is 19.40%, which is 45% above median its own 10-year median of 13.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raily Aesthetic Medicine International Holdings stock overvalued right now?
Based on GuruFocus' analysis, Raily Aesthetic Medicine International Holdings (HKSE:02135) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.12 — trading 15% below its estimated fair value. The current EBITDA Margin % is 19.40%, which is 45% above median its 10-year median of 13.34 and 89.5% above the Healthcare Providers & Services industry median of 10.24. Raily Aesthetic Medicine International Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Raily Aesthetic Medicine International Holdings (HKSE:02135), the current EBITDA Margin % is 19.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raily Aesthetic Medicine International Holdings (HKSE:02135) Overvalued in 2026?
Based on GuruFocus' analysis, Raily Aesthetic Medicine International Holdings stock appears to be undervalued.
The current stock price of HK$0.12 is trading 15% below its estimated GF Value™ of HK$0.14.
GuruFocus considers Raily Aesthetic Medicine International Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:02135:
EBITDA Margin %: 19.40% (45% above median its 10-year median of 13.34)
GF Value™: HK$0.14 vs. price of HK$0.12 (15% below fair value)
Industry Position: 89.5% above the Healthcare Providers & Services median (#278 of 664)
No single metric tells the full story. See the HKSE:02135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raily Aesthetic Medicine International Holdings Ltd is an investment holding company. The company were principally engaged in the provision of aesthetic medical services, sale of aesthetic medical equipment products and provision of consulting services. The group is organized into three reportable operating segments namely Aesthetic medical services comprise principally inpatient services including surgical services and outpatient services including injection service, dermatology service and others; Aesthetic medical equipment products comprise principally sales of collagen injection products, surgical implants and aesthetic medical skincare products; Consulting services comprise principally management consulting services of which majority of revenue comes from Aesthetic medical services.
47GF Score
Get the complete analysis for HKSE:02135
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02135 has been successfully added to your 
